Sumanta Pal, MD is the co-director of City of Hope’s Kidney Cancer Program and is the head of the kidney and bladder cancer disease team at the institution. www.cityofhope.org
Dr. Pal is an internationally recognized leader in medical oncology, specializing in genitourinary cancers, including kidney, bladder and prostate cancer. After completing his medical training and residency at the University of California, Los Angeles, Dr. Pal consequently undertook a fellowship program at City of Hope’s comprehensive cancer center.
Dr. Pal currently upholds one of the largest kidney and bladder cancer research clinical trial portfolios along the west coast and has developed an integrated program focusing on collaborations with urologists in the Department of Surgery and with researchers at the Beckman Research Institute at City of Hope.
He has published over 150 peer-reviewed articles, featured in leading journals including the Lancet Oncology, Cancer Cell, and The Journal of Clinical Oncology.
Dr. Pal’s research focuses on the stimulation of collaborative research across multiple departments, with the aim of discovering new therapeutic approaches for currently incurable diseases. Dr. Pal now also holds patents for novel prostate cancer drugs currently under development.